Review
Cardiac & Cardiovascular Systems
Rosanne F. Vogel, Ronak Delewi, Lina Badimon, Dominick J. Angiolillo, Georgios J. Vlachojannis
Summary: Since the early 20th century, the treatment of myocardial infarction has evolved extensively, including mechanical revascularization therapies and pharmacological therapies. Currently, antiplatelet therapy and anticoagulation therapy are the mainstay of pharmacological treatment. Despite the availability of several drugs, the search for novel potent agents continues to balance treatment efficacy and safety.
REVIEWS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Krishnaraj S. Rathod, Katrina Comer, Oliver Casey-Gillman, Lizzie Moore, Gordon Mills, Gordon Ferguson, Sotiris Antoniou, Riyaz Patel, Sadeer Fhadil, Tasleem Damani, Paul Wright, Mick Ozkor, Debashish Das, Oliver P. Guttmann, Andreas Baumbach, R. Andrew Archbold, Andrew Wragg, Ajay K. Jain, Fizzah A. Choudry, Anthony Mathur, Daniel A. Jones
Summary: This study demonstrated the safety and feasibility of early hospital discharge for low-risk STEMI patients following successful primary PCI. The structured, multidisciplinary virtual follow-up schedule supported pathway helped achieve a favorable outcome with low cardiovascular mortality and MACE rates compared to a control group of patients who stayed in the hospital for >48 hours.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
(2021)
Article
Cardiac & Cardiovascular Systems
Enrico Fabris, Sara Menzio, Caterina Gregorio, Andrea Pezzato, Davide Stolfo, Aneta Aleksova, Giancarlo Vitrella, Serena Rakar, Andrea Perkan, Arnoud W. J. Van't Hof, Gianfranco Sinagra
Summary: This study investigates the timing of antithrombotic therapy administration in ST-elevation myocardial infarction (STEMI) patients. The results show that early pretreatment strategy leads to improved basal reperfusion, reduced infarct size, and higher left ventricular ejection fraction at discharge. This highlights the importance of efficient treatment strategies for STEMI patients.
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS
(2022)
Article
Medicine, General & Internal
Andras Mester, Nora Rat, Theodora Benedek, Diana Opincariu, Roxana Hodas, Monica Chitu, Imre Benedek
Summary: This study investigated the relationship between acute inflammatory response and the extent of myocardial scarring as measured by CMR in STEMI patients. The results showed that IL-6 and day-5 hs-CRP levels can predict the size and transmurality of the scar, and day-5 hs-CRP levels are independent predictors of 2-year mortality. The CMR pattern of myocardial scarring after revascularization is a significant predictor for 2-year mortality in STEMI patients.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Li Song, Xiaoxiao Zhao, Runzhen Chen, Jiannan Li, Jinying Zhou, Chen Liu, Peng Zhou, Ying Wang, Yi Chen, Hanjun Zhao, Hongbing Yan
Summary: This study found that high PCSK9 levels were independently associated with major adverse cardiovascular events (MACEs) in ST-segment elevation myocardial infarction (STEMI) patients with diabetes undergoing primary percutaneous coronary intervention (PCI). This association may be due to the stronger correlations between PCSK9 and inflammation and platelet activation markers in diabetic patients.
CARDIOVASCULAR DIABETOLOGY
(2022)
Article
Multidisciplinary Sciences
Dominika Domokos, Andras Szabo, Gyongyver Banhegyi, Laszlo Major, Robert Gabor Kiss, David Becker, Istvan Ferenc Edes, Zoltan Ruzsa, Bela Merkely, Istvan Hizoh
Summary: The study suggests that the use of intravenous morphine may have no impact on long-term mortality and predischarge ejection fraction in ST-segment elevation myocardial infarction (STEMI) patients treated with primary PCI.
Article
Cardiac & Cardiovascular Systems
Yu Qi, Rong Gu, Jiamin Xu, Lina Kang, Yihai Liu, Lian Wang, Jianzhou Chen, Jingmei Zhang, Kun Wang
Summary: The study found that IMR is correlated with perfusion grade and ST-segment resolution, with patients with high IMR having significantly lower LVEF at 3 months and 1 year compared to those with low IMR. IMR is negatively correlated with LVEF.
BMC CARDIOVASCULAR DISORDERS
(2021)
Article
Immunology
Xiaoxiao Zhao, Li Song, Ying Wang, Jiannan Li, Jinying Zhou, Runzhen Chen, Chen Liu, Peng Zhou, Zhaoxue Sheng, Yi Chen, Hanjun Zhao, Hongbing Yan
Summary: This prospective study aimed to determine the prognostic value of combined measures of plasma PCSK9 and PTX3 in STEMI patients undergoing primary PCI. The study found that elevated levels of both PCSK9 and PTX3 were associated with an increased risk of MACE, particularly among patients with plaque erosion.
JOURNAL OF INFLAMMATION RESEARCH
(2021)
Article
Emergency Medicine
Xuhe Gong, Li Zhou, Tianhui Dong, Xiaosong Ding, Huiqiang Zhao, Hui Chen, Hongwei Li
Summary: The COVID-19 pandemic has affected the emergency treatment of patients with ST-segment elevation myocardial infarction (STEMI), resulting in longer symptom-to-first medical contact and door-to-balloon times. However, the pandemic is not independently associated with in-hospital major adverse cardiac events among patients undergoing primary PCI.
AMERICAN JOURNAL OF EMERGENCY MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
David Adlam, Maciej Zarebinski, Neal G. Uren, Pawel Ptaszynski, Keith G. Oldroyd, Shahzad Munir, Azfar Zaman, Hussain Contractor, Robert Gabor Kiss, Istvan Edes, Joanna Szachniewicz, Gergely Gyorgy Nagy, Mario J. Garcia, Janos Tomcsanyi, John Irving, Andrew S. P. Sharp, Piotr Musialek, Geza Lupkovics, Cheerag Shirodaria, Joseph B. Selvanayagam, Pauline Quinn, Leong Ng, Mark Roth, Michael A. Insko, Ben Haber, Stephen Hill, Lori Siegel, Simon Tulloch, Keith M. Channon
Summary: The study showed that giving FDY-5301 prior to PPCI in first-time STEMI patients increased plasma iodide levels and reduced myocardial damage in some patients after infarction, while also being safe and feasible.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2022)
Article
Medicine, General & Internal
Xiangming Hu, Xing Yang, Xida Li, Guang Li, Yingling Zhou, Haojian Dong
Summary: Elevated serum uric acid is associated with a higher incidence of no/slow-reflow phenomenon in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention, especially in those with delayed perfusion or diabetes mellitus. It is related to severe inflammation and worse left ventricular ejection fraction.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
(2022)
Review
Cardiac & Cardiovascular Systems
Enrico Fabris, Abi Selvarajah, Annerieke Tavenier, Rik Hermanides, Elvin Kedhi, Gianfranco Sinagra, Arnoud Van't Hof
Summary: Antithrombotic therapy is crucial for primary PCI, but acute management of STEMI patients involves pain relief and cardioprotection. Recent evidence questions the safety and efficacy of some commonly used treatments, and additional strategies have shown disappointing results.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS
(2022)
Article
Medicine, General & Internal
Simona Giubilato, Fabiana Luca, Andrea Pozzi, Giorgio Caretta, Stefano Cornara, Anna Pilleri, Concetta Di Nora, Francesco Amico, Irene Di Matteo, Silvia Favilli, Roberta Rossini, Carmine Riccio, Furio Colivicchi, Michele Massimo Gulizia
Summary: The combination of OAC and DAPT is commonly used for AF patients with ACS and/or undergoing PCI, but it increases the risk of bleeding. TAT, typically consisting of OAC and DAPT, should be limited to one week after ACS and/or PCI, unless there is a high ischemic risk. In that case, TAT can be continued for up to one month. DOAC should be preferred over VKA in TAT or DAPT due to its favorable risk/benefit profile.
JOURNAL OF CLINICAL MEDICINE
(2022)
Editorial Material
Medicine, General & Internal
E. Magnus Ohman
Summary: For patients with drug-eluting stents undergoing PCI, prolonged dual antiplatelet therapy is essential to prevent stent thrombosis. Advances in technology have led to newer stents with reduced thrombotic risk while maintaining anti-restenosis properties.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Review
Medicine, General & Internal
Leonardo De Luca, Raffaella Mistrulli, Francesco Antonio Veneziano, Francesco Grigioni, Massimo Volpe, Francesco Musumeci, Domenico Gabrielli
Summary: Patients with atrial fibrillation (AF) have an increased risk for coronary artery disease (CAD) after PCI, requiring a delicate balance of antithrombotic therapy to reduce ischemic and bleeding risks. Recent studies show that dual-antithrombotic therapy (DAT) can reduce bleeding events compared to triple-antithrombotic therapy (TAT), and direct-acting oral anticoagulants (DOACs) may have similar benefits over vitamin K antagonist (VKA).
JOURNAL OF CLINICAL MEDICINE
(2022)